Total Payments
$40,588
2024 Payments
$7,920
Companies
7
Transactions
38
Medicare Patients
2,150
Medicare Billing
$176,297
Payment Breakdown by Category
Consulting$27,881 (68.7%)
Other$7,504 (18.5%)
Research$3,451 (8.5%)
Travel$1,282 (3.2%)
Food & Beverage$469.77 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,881 | 17 | 68.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,504 | 9 | 18.5% |
| Unspecified | $3,451 | 8 | 8.5% |
| Travel and Lodging | $1,282 | 2 | 3.2% |
| Food and Beverage | $469.77 | 2 | 1.2% |
Payments by Type
General
$37,137
30 transactions
Research
$3,451
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $17,644 | 22 | $0 (2024) |
| Roche Products Limited | $8,300 | 6 | $0 (2022) |
| Neurocrine Biosciences, Inc. | $6,370 | 3 | $0 (2024) |
| Sage Therapeutics, Inc. | $3,717 | 2 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $2,805 | 1 | $0 (2021) |
| Acorda Therapeutics, Inc | $1,678 | 3 | $0 (2017) |
| Medtronic, Inc. | $73.28 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,920 | 4 | Neurocrine Biosciences, Inc. ($4,000) |
| 2023 | $5,157 | 4 | Sage Therapeutics, Inc. ($2,124) |
| 2022 | $2,423 | 2 | Sage Therapeutics, Inc. ($1,593) |
| 2021 | $7,205 | 5 | Roche Products Limited ($4,150) |
| 2020 | $3,201 | 7 | F. Hoffmann-La Roche AG ($3,201) |
| 2019 | $13,003 | 13 | F. Hoffmann-La Roche AG ($9,683) |
| 2017 | $1,678 | 3 | Acorda Therapeutics, Inc ($1,678) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 08/20/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 05/16/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 03/19/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 11/30/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,120.00 | General |
| 11/24/2023 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,124.00 | General |
| 09/12/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| 01/18/2023 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $73.28 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 08/09/2022 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,593.00 | General |
| 01/06/2022 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $830.00 | General |
| 12/03/2021 | Neurocrine Biosciences, Inc. | — | — | Cash or cash equivalent | $250.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBENAZINE FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON DISEASE | ||||||
| 11/01/2021 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| 10/29/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,805.00 | General |
| 05/04/2021 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $622.50 | General |
| 03/18/2021 | Roche Products Limited | — | Consulting Fee | Cash or cash equivalent | $2,282.50 | General |
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $419.65 | Research |
| Study: Patient and physician perspectives on the care and assistance needs in Huntington's disease • Category: None | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $419.65 | Research |
| Study: Impact of caring for patients with Huntington's disease on work status • Category: None | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $627.67 | Research |
| Study: Patient and physician perspectives on the care and assistance needs in Huntington's disease • Category: None | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $627.67 | Research |
| Study: Patterns of genetic testing in Huntington's disease • Category: None | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $391.05 | Research |
| Study: Patient and physician perspectives on the care and assistance needs in Huntington's disease • Category: None | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $373.44 | Research |
| Study: Impact of caring for patients with Huntington's disease on work status • Category: None | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $342.17 | Research |
| Study: Patterns of genetic testing in Huntington's disease • Category: None | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,639.19 | General |
| Category: None | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $711.02 | General |
| Category: None | ||||||
| 10/25/2019 | Roche Products Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Patient and physician perspectives on the care and assistance needs in Huntington's disease | F. Hoffmann-La Roche AG | $1,438 | 3 |
| Patterns of genetic testing in Huntington's disease | F. Hoffmann-La Roche AG | $969.84 | 2 |
| Impact of caring for patients with Huntington's disease on work status | F. Hoffmann-La Roche AG | $793.09 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBENAZINE FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON DISEASE | Neurocrine Biosciences, Inc. | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 474 | 569 | $220,601 | $41,659 |
| 2022 | 7 | 545 | 681 | $241,162 | $48,032 |
| 2021 | 9 | 574 | 700 | $194,738 | $51,759 |
| 2020 | 10 | 557 | 670 | $157,200 | $34,847 |
Total Patients
2,150
Total Services
2,620
Medicare Billing
$176,297
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 193 | 243 | $80,925 | $15,196 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 137 | 165 | $81,701 | $14,533 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $23,730 | $5,196 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 79 | 96 | $21,762 | $4,207 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 27 | 27 | $12,483 | $2,528 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 222 | 298 | $93,899 | $17,927 | 19.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 136 | 172 | $79,984 | $16,182 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 59 | 59 | $34,723 | $6,702 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 84 | 102 | $21,770 | $4,398 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $5,200 | $1,140 | 21.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 19 | 19 | $2,945 | $1,112 | 37.8% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Facility | 2022 | 13 | 19 | $2,641 | $572.05 | 21.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 199 | 266 | $67,512 | $17,094 | 25.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 123 | 160 | $57,164 | $16,016 | 28.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 57 | 57 | $30,768 | $7,712 | 25.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 104 | 120 | $19,720 | $5,044 | 25.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 16 | 16 | $6,624 | $1,700 | 25.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 23 | 25 | $3,084 | $1,447 | 46.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 18 | 18 | $5,850 | $1,397 | 23.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 22 | 23 | $1,916 | $867.41 | 45.3% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Facility | 2021 | 12 | 15 | $2,100 | $482.02 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 234 | 318 | $76,183 | $14,801 | 19.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 34 | 34 | $17,285 | $3,801 | 22.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 42 | $14,115 | $3,187 | 22.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 74 | 81 | $12,602 | $2,709 | 21.5% |
About Martha Nance
Martha Nance is a Neurology healthcare provider based in St Louis Park, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457338592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Martha Nance has received a total of $40,588 in payments from pharmaceutical and medical device companies, with $7,920 received in 2024. These payments were reported across 38 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($27,881).
As a Medicare-enrolled provider, Nance has provided services to 2,150 Medicare beneficiaries, totaling 2,620 services with total Medicare billing of $176,297. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location St Louis Park, MN
- Active Since 12/29/2005
- Last Updated 10/07/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1457338592
Products in Payments
- Non-Covered Product (Drug) $16,204
- PERCEPT PC BRAINSENSE (Device) $73.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in St Louis Park
Tanaporn Rasameesoraj, M.d, M.D
Neurology — Payments: $57,664
Neurology $57,664
Sydney Spagna, Md, MD
Neurology — Payments: $21,118
Neurology $21,118
Frederick Taylor
Neurology — Payments: $3,899
Neurology $3,899
Jeanne Beattie, M.d, M.D
Neurology — Payments: $3,067
Neurology $3,067
Dr. Sotirios Parashos, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $1,760
Neurology $1,760
Armin Jewell, D.o, D.O
Neurology — Payments: $931.74
Neurology $931.74